Colorectal cancer

Authors and affiliations:
Sara P. S. P. Moura ^1,2, Silvia Marín ^3,4, Ismael Rufino ⁵, Rita C. Guedes ⁵, Marta Cascante ^3,4 and Jorge A. R. Salvador ^1,2

¹ Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal

² Center for Neuroscience and Cell Biology (CNC), University of Coimbra, 3004-504 Coimbra, Portugal

A recent study, led by Ricardo Marcos-Pinto and Ângela Fernandes, with Henrique Fernandes-Mendes as its first author, revealed associations between aberrant glycoprofiles and clinical variables. This study, conducted in the Immunology, Cancer & Glycomedicine group at i3S (led by Salomé Pinho), reveals an association between the levels of branched N-glycans in epithelial cells and factors such as age, smoking and polyp dimension, suggesting a link between these glycans and colorectal cancer progression.

Authors and affiliations:
Joana FS Pereira, Cláudia Bessa, Paulo Matos and Peter Jordan

Authors and Affiliations:

Flávia Pereira ^1,2,3,4, Anabela Ferreira ^1,2, Celso Albuquerque Reis ^3,5,6, Maria João Sousa ^1,2, Maria José Oliveira ^3,4,5 and Ana Preto ^1,2

¹ Centre of Molecular and Environmental Biology (CBMA), Department of Biology, Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal

Patients with inflammatory bowel disease (IBD), which includes Crohn's Disease and Ulcerative Colitis, are at increased risk of developing colorectal cancer (CRC) when compared to the general population. Colorectal cancer associated with long-lasting (more than 8-10 years of diagnosis) bowel inflammation (colitis) is one of the major complications of inflammatory bowel disease. The mechanisms underlying the progression of inflammation to bowel cancer are not fully understood.

Authors and Affiliations:

Bruna Costa: Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal

Susana Ferreira: Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal

Vanda Póvoa: Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal

Oriol Parés: Radiation Oncology Department, Champalimaud Clinical Centre, Champalimaud Foundation, 1400-038 Lisbon, Portugal

Até à data não existe um método capaz de determinar de forma inequívoca se, para um dado doente oncológico, a radioterapia é, ou não, um tratamento eficaz. Trata-se de um problema de extrema relevância, uma vez que implica que alguns doentes estão a ser desnecessariamente submetidos a efeitos colaterais potencialmente graves da radioterapia. Um novo ensaio, recorrendo a avatares de peixe-zebra, poderá oferecer uma solução promissora com testes rápidos e personalizados de compatibilidade com radioterapia.

Virtual event, Worldwide

23 - 24 March, 2020

See more informations here: https://www.eacr.org/conference/molecularpathology2021virtual?utm_source=confseriespage&utm_medium=web&utm_campaign=vMP21&utm_content=